请输入您要查询的百科知识：

　

词条 Phenobarbital
释义

  1. Medical uses

      Other uses  

  2. Side effects

  3. Contraindications

  4. Overdose

  5. Mechanism of action

  6. Pharmacokinetics

  7. Veterinary uses

  8. History

  9. Names

  10. Synthesis

  11. Regulation

  12. References

  13. External links

{{distinguish|Pentobarbital}}{{Redirect|Haplos|the TV series|Haplos (TV series)}}{{Infobox drug
| verifiedrevid = 464200457
| IUPAC_name = 5-Ethyl-5-phenyl-1,3-diazinane-2,4,6-trione
| image = Phenobarbital2DACS.svg
| width = 120px
| alt = 2D chemical structure of phenobarbital
| image2 = Phenobarbital ball-and-stick.png
| alt2 = 3D ball-and-stick model of phenobarbital
| tradename = Luminal
| Drugs.com = {{drugs.com|monograph|phenobarbital}}
| MedlinePlus = a682007
| pregnancy_AU = D
| pregnancy_US = D
| legal_AU = S4
| legal_CA = Schedule IV
| legal_DE = Rx-only/Anlage III
| legal_UK = Class B
| legal_US = Schedule IV
| dependency_liability = Low[1]
| routes_of_administration = by mouth (PO), rectal (PR), parenteral (intramuscular and intravenous)
| bioavailability = >95%
| protein_bound = 20 to 45%
| metabolism = Liver (mostly CYP2C19)
| onset = within 5 min (IV) and 30 min (PO)[2]
| elimination_half-life = 53 to 118 hours
| duration_of_action= 4 hrs[2] to 2 days[4]
| excretion = Kidney and fecal
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50-06-6
| ATC_prefix = N05
| ATC_suffix = CA24
| ATC_supplemental = {{ATC|N03|AA02}}
| PubChem = 4763
| IUPHAR_ligand = 2804
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB01174
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 4599
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = YQE403BP4D
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00506
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 8069
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 40
| C=12
| H=12
| N=2
| O=3
| molecular_weight = 232.235 g/mol
| smiles = O=C1NC(=O)NC(=O)C1(c2ccccc2)CC
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C12H12N2O3/c1-2-12(8-6-4-3-5-7-8)9(15)13-11(17)14-10(12)16/h3-7H,2H2,1H3,(H2,13,14,15,16,17)
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = DDBREPKUVSBGFI-UHFFFAOYSA-N
}}Phenobarbital, also known as phenobarbitone or phenobarb, is a medication recommended by the World Health Organization for the treatment of certain types of epilepsy in developing countries.[2] In the developed world, it is commonly used to treat seizures in young children,[3] while other medications are generally used in older children and adults.[4] It may be used intravenously, injected into a muscle, or taken by mouth.[2] The injectable form may be used to treat status epilepticus.[2] Phenobarbital is occasionally used to treat trouble sleeping, anxiety, and drug withdrawal and to help with surgery.[5] It usually begins working within five minutes when used intravenously and half an hour when administered orally.[5] Its effects last for between four hours and two days.[5][6]

Side effects include a decreased level of consciousness along with a decreased effort to breathe.[5] There is concern about both abuse and withdrawal following long-term use.[5] It may also increase the risk of suicide.[5] It is pregnancy category B or D (depending on how it is taken) in the United States and category D in Australia, meaning that it may cause harm when taken by pregnant women.[5][7] If used during breastfeeding it may result in drowsiness in the baby.[8] A lower dose is recommended in those with poor liver or kidney function, as well as elderly people.[5] Phenobarbital is a barbiturate that works by increasing the activity of the inhibitory neurotransmitter GABA.[5]

Phenobarbital was discovered in 1912 and is the oldest still commonly used anti-seizure medication.[9][10] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[11] It is the least expensive anti-seizure medication at around US$5 a year in the developing world.[25] Access, however, may be difficult as some countries label it as a controlled drug.[12]

Medical uses

Phenobarbital is used in the treatment of all types of seizures, except absence seizures.[13][14] It is no less effective at seizure control than phenytoin, however phenobarbital is not as well tolerated.[15] Phenobarbital may provide a clinical advantage over carbamazepine for treating partial onset seizures. Carbamazepine may provide a clinical advantage over phenobarbital for generalized onset tonic-clonic seizures.[16] Its very long active half-life (53–118 hours) means for some people doses do not have to be taken every day, particularly once the dose has been stabilized over a period of several weeks or months, and seizures are effectively controlled.{{Citation needed|date=January 2017}}

The first-line drugs for treatment of status epilepticus are benzodiazepines, such as lorazepam or diazepam. If these fail, then phenytoin may be used, with phenobarbital being an alternative in the US, but used only third-line in the UK.[17] Failing that, the only treatment is anaesthesia in intensive care.[14][18] The World Health Organization (WHO) gives phenobarbital a first-line recommendation in the developing world and it is commonly used there.[2][19]

Phenobarbital is the first-line choice for the treatment of neonatal seizures.[20][21][22] Concerns that neonatal seizures in themselves could be harmful make most physicians treat them aggressively. No reliable evidence, though, supports this approach.[23]

Phenobarbital is sometimes used for alcohol detoxification and benzodiazepine detoxification for its sedative and anti-convulsant properties. The benzodiazepines chlordiazepoxide (Librium) and oxazepam (Serax) have largely replaced phenobarbital for detoxification.[24]

While phenobarbital has been used for insomnia, such use is not recommended due to the risk of addiction and other side affects.[25]

Other uses

Phenobarbital properties can effectively reduce tremors and seizures associated with abrupt withdrawal from benzodiazepines.

Phenobarbital is a cytochrome P450 inducer, and is used to reduce the toxicity of some drugs.

Phenobarbital is occasionally prescribed in low doses to aid in the conjugation of bilirubin in people with Crigler-Najjar syndrome (Type II),[26] or in patients with Gilbert syndrome.{{citation needed|date=May 2016}}

Phenobarbital can also be used to relieve cyclic vomiting syndrome symptoms.

Phenobarbital is a commonly used agent in high purity and dosage for lethal injection of "death row" criminals.

In infants suspected of neonatal biliary atresia, phenobarbital is used in preparation for a 99mTc-IDA hepatobiliary (HIDA; hepatobiliary 99mTc-iminodiacetic acid) study that differentiates atresia from hepatitis or cholestasis.

Phenobarbital is used as a secondary agent to treat newborns with neonatal abstinence syndrome, a condition of withdrawal symptoms from exposure to opioid drugs in utero.

In massive doses, phenobarbital is prescribed to terminally ill patients to allow them to end their life through physician-assisted suicide.[27]

Like other barbiturates, phenobarbital can be used recreationally,[28] but this is reported to be relatively infrequent.[29]

Side effects

Sedation and hypnosis are the principal side effects (occasionally, they are also the intended effects) of phenobarbital. Central nervous system effects, such as dizziness, nystagmus and ataxia, are also common. In elderly patients, it may cause excitement and confusion, while in children, it may result in paradoxical hyperactivity.[30]

Phenobarbital is a cytochrome P450 hepatic enzyme inducer. It binds transcription factor receptors that activate cytochrome P450 transcription, thereby increasing its amount and thus its activity. Due to this higher amount of CYP450, drugs that are metabolized by the CYP450 enzyme system will have decreased effectiveness. This is because the increased CYP450 activity increases the clearance of the drug, reducing the amount of time they have to work.[31]

Caution is to be used with children. Among anti-convulsant drugs, behavioural disturbances occur most frequently with clonazepam and phenobarbital.[32]

Contraindications

Acute intermittent porphyria, hypersensitivity to any barbiturate, prior dependence on barbiturates, severe respiratory insufficiency (as with chronic obstructive pulmonary disease), severe liver failure, pregnancy, and breastfeeding are contraindications for phenobarbital use.[30]

Overdose

{{Main|Barbiturate overdose}}

Phenobarbital causes a depression of the body's systems, mainly the central and peripheral nervous systems. Thus, the main characteristic of phenobarbital overdose is a "slowing" of bodily functions, including decreased consciousness (even coma), bradycardia, bradypnea, hypothermia, and hypotension (in massive overdoses). Overdose may also lead to pulmonary edema and acute renal failure as a result of shock, and can result in death.

The electroencephalogram (EEG) of a person with phenobarbital overdose may show a marked decrease in electrical activity, to the point of mimicking brain death. This is due to profound depression of the central nervous system, and is usually reversible.[33]

Treatment of phenobarbital overdose is supportive, and mainly consists of the maintenance of airway patency (through endotracheal intubation and mechanical ventilation), correction of bradycardia and hypotension (with intravenous fluids and vasopressors, if necessary), and removal of as much drug as possible from the body. Depending on how much time has elapsed since ingestion of the drug, this may be accomplished through gastric lavage (stomach pumping) or use of activated charcoal. Hemodialysis is effective in removing phenobarbital from the body, and may reduce its half-life by up to 90%.[33] No specific antidote for barbiturate poisoning is available.[34]

British veterinarian Donald Sinclair, better known as the character Siegfried Farnon in the "All Creatures Great and Small" book series by James Herriot, committed suicide at the age of 84 by injecting himself with an overdose of phenobarbital. Activist Abbie Hoffman also committed suicide by consuming phenobarbital, combined with alcohol, on April 12, 1989; the residue of around 150 pills was found in his body at autopsy.[35] Also dying from an overdose in 1996 was actress/model Margaux Hemingway. The Japanese officers aboard the German submarine U-234 killed themselves with phenobarbital while the German crew members were on their way to the US to surrender (but before Japan had surrendered).

Thirty-nine members of the Heaven's Gate UFO religious group committed mass suicide in March 1997 by drinking a lethal dose of phenobarbital and vodka "and then lay down to die" hoping to enter an alien spacecraft.[36]

Mechanism of action

Through its action on GABAA receptors, phenobarbital increases the flow of chloride ions into the neuron which decreases the excitability of the post-synaptic neuron. Hyperpolarizing this post-synaptic membrane leads to a decrease in the general excitatory aspects of the post-synaptic neuron. By making it harder to depolarize the neuron, the threshold for the action potential of the post-synaptic neuron will be increased. Phenobarbital stimulates GABA to accomplish this hyperpolarization.[37] Direct blockade of excitatory glutamate signaling is also believed to contribute to the hypnotic/anticonvulsant effect that is observed with the barbiturates.[38]

Pharmacokinetics

Phenobarbital has an oral bioavailability of about 90%. Peak plasma concentrations (Cmax) are reached eight to 12 hours after oral administration. It is one of the longest-acting barbiturates available – it remains in the body for a very long time (half-life of two to seven days) and has very low protein binding (20 to 45%). Phenobarbital is metabolized by the liver, mainly through hydroxylation and glucuronidation, and induces many isozymes of the cytochrome P450 system. Cytochrome P450 2B6 (CYP2B6) is specifically induced by phenobarbital via the CAR/RXR nuclear receptor heterodimer. It is excreted primarily by the kidneys.[39]

Veterinary uses

Phenobarbital is one of the initial drugs of choice to treat epilepsy in dogs, and is the initial drug of choice to treat epilepsy in cats.[40]

It is also used to treat feline hyperesthesia syndrome in cats when anti-obsessional therapies prove ineffective.[41]

It may also be used to treat seizures in horses when benzodiazepine treatment has failed or is contraindicated.[42]

History

The first barbiturate drug, barbital, was synthesized in 1902 by German chemists Emil Fischer and Joseph von Mering and was first marketed as Veronal by Friedr. Bayer et comp. By 1904, several related drugs, including phenobarbital, had been synthesized by Fischer. Phenobarbital was brought to market in 1912 by the drug company Bayer as the brand Luminal. It remained a commonly prescribed sedative and hypnotic until the introduction of benzodiazepines in the 1960s.[43]

Phenobarbital's soporific, sedative and hypnotic properties were well known in 1912, but it was not yet known to be an effective anti-convulsant. The young doctor Alfred Hauptmann[44] gave it to his epilepsy patients as a tranquilizer and discovered their seizures were susceptible to the drug. Hauptmann performed a careful study of his patients over an extended period. Most of these patients were using the only effective drug then available, bromide, which had terrible side effects and limited efficacy. On phenobarbital, their epilepsy was much improved: The worst patients suffered fewer and lighter seizures and some patients became seizure-free. In addition, they improved physically and mentally as bromides were removed from their regimen. Patients who had been institutionalised due to the severity of their epilepsy were able to leave and, in some cases, resume employment. Hauptmann dismissed concerns that its effectiveness in stalling seizures could lead to patients suffering a build-up that needed to be "discharged". As he expected, withdrawal of the drug led to an increase in seizure frequency – it was not a cure. The drug was quickly adopted as the first widely effective anti-convulsant, though World War I delayed its introduction in the U.S.[45]

In 1939, a German family asked Adolf Hitler to have their disabled son killed; the five-month-old boy was given a lethal dose of Luminal after Hitler sent his own doctor to examine him. A few days later 15 psychiatrists were summoned to Hitler's Chancellery and directed to commence a clandestine euthanasia program.[46][47]

In 1940, at a clinic in Ansbach, Germany, around 50 intellectually disabled children were injected with Luminal and killed that way. A plaque was erected in their memory in 1988 in the local hospital at Feuchtwanger Strasse 38, although a newer plaque does not mention that patients were killed using barbiturates on site.[48][49] Luminal was used in the Nazi children's euthanasia program until at least 1943.[50][51]

Phenobarbital was used to treat neonatal jaundice by increasing liver metabolism and thus lowering bilirubin levels. In the 1950s, phototherapy was discovered, and became the standard treatment.[52]

Phenobarbital was used for over 25 years as prophylaxis in the treatment of febrile seizures.[53] Although an effective treatment in preventing recurrent febrile seizures, it had no positive effect on patient outcome or risk of developing epilepsy. The treatment of simple febrile seizures with anticonvulsant prophylaxis is no longer recommended.[54][55]

Names

Phenobarbital is the INN and phenobarbitone is the BAN.

Synthesis

Barbiturate drugs are obtained via condensation reactions between a derivative of diethyl malonate and urea in the presence of a strong base.[56] The synthesis of phenobarbital uses this common approach as well but differs in the way in which this malonate derivative is obtained. The reason for this difference is due to the fact that aryl halides do not typically undergo nucleophilic substitution in Malonic ester synthesis in the same way as aliphatic organosulfates or halocarbons do.[57] To overcome this lack of chemical reactivity two dominant synthetic approaches using benzyl cyanide as a starting material have been developed:

The first of these methods consists of a Pinner reaction of benzyl cyanide, giving phenylacetic acid ethyl ester.[58] Subsequently, this ester undergoes cross Claisen condensation using diethyl oxalate, giving diethyl ester of phenyloxobutandioic acid. Upon heating this intermediate easily loses carbon monoxide, yielding diethyl phenylmalonate.[59] Malonic ester synthesis using ethyl bromide leads to the formation of α-phenyl-α-ethylmalonic ester. Finally a condensation reaction with urea gives phenobarbital.[56]

The second approach utilizes diethyl carbonate in the presence of a strong base to give α-phenylcyanoacetic ester.[60][61] Alkylation of this ester using ethyl bromide proceeds via a nitrile anion intermediate to give the α-phenyl-α-ethylcyanoacetic ester.[62] This product is then further converted into the 4-iminoderivative upon condensation with urea. Finally acidic hydrolysis of the resulting product gives phenobarbital.[63]

Regulation

The level of regulation includes Schedule IV Non-Narcotic (depressant) (ACSCN 2285) in the United States under the Controlled Substances Act 1970—but along with a few other barbiturates and at least one benzodiazepine, and codeine, dionine, or dihydrocodeine at low concentrations, it also has exempt prescription and had at least one exempt OTC combination drug now more tightly regulated for its ephedrine content.[64] The phenobarbitone/phenobarbital exists in subtherapeutic doses which add up to an effective dose to counter the overstimulation and possible seizures from a deliberate overdose in ephedrine tablets for asthma, which are now regulated at the federal and state level as: a restricted OTC medicine and/or watched precursor, uncontrolled but watched/restricted prescription drug & watched precursor, a Schedule II, III, IV, or V prescription-only controlled substance & watched precursor, or a Schedule V (which also has possible regulations at the county/parish, town, city, or district as well aside from the fact that the pharmacist can also choose not to sell it, and photo ID and signing a register is required) exempt Non-Narcotic restricted/watched OTC medicine.[65]

References

1. ^{{cite book|last1=Bassert|first1=Joanna M.|title=McCurnin's Clinical Textbook for Veterinary Technicians - E-Book|date=2017|publisher=Elsevier Health Sciences|isbn=9780323496407|page=955|url=https://books.google.de/books?id=9ARODgAAQBAJ&pg=PA955|language=en}}
2. ^1 {{cite journal|last=Ilangaratne|first=NB|author2=Mannakkara, NN |author3=Bell, GS |author4= Sander, JW |title=Phenobarbital: missing in action.|journal=Bulletin of the World Health Organization|date=Dec 1, 2012|volume=90|issue=12|pages=871–871A|pmid=23284189|doi=10.2471/BLT.12.113183 |pmc=3524964}}
3. ^{{cite journal|last1=Brodie|first1=MJ|last2=Kwan|first2=P|title=Current position of phenobarbital in epilepsy and its future.|journal=Epilepsia|date=December 2012|volume=53 Suppl 8|pages=40–6|pmid=23205961|doi=10.1111/epi.12027}}
4. ^{{cite web|title=The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care NICE guidelines [CG137]|website=National Institute for Health and Care Excellence|date=January 2012}}
5. ^1 2 3 4 5 6 7 8 9 10 11 12 {{cite web|title=Phenobarbital|url=https://www.drugs.com/monograph/phenobarbital.html|publisher=The American Society of Health-System Pharmacists|accessdate=Aug 14, 2015|deadurl=no|archiveurl=https://web.archive.org/web/20150906225702/http://www.drugs.com/monograph/phenobarbital.html|archivedate=2015-09-06|df=}}
6. ^1 {{cite book|last1=Marx|first1=John A.|title=Rosen's emergency medicine : concepts and clinical practice|date=2010|publisher=Mosby/Elsevier|location=Philadelphia|isbn=978-0-323-05472-0|page=1352|edition=7|url=https://books.google.ca/books?id=u7TNcpCeqx8C&pg=PA1352|deadurl=no|archiveurl=https://web.archive.org/web/20160305025648/https://books.google.ca/books?id=u7TNcpCeqx8C&pg=PA1352|archivedate=2016-03-05|df=}}
7. ^{{cite web|title=Prescribing medicines in pregnancy database|url=http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw|work=Australian Government|accessdate=22 April 2014|date=3 March 2014|deadurl=no|archiveurl=https://web.archive.org/web/20140408040902/http://www.tga.gov.au/hp/medicines-pregnancy.htm#.U1Yw8Bc3tqw|archivedate=8 April 2014|df=}}
8. ^{{cite web|title=Phenobarbital use while Breastfeeding|url=https://www.drugs.com/breastfeeding/phenobarbital.html|accessdate=14 August 2015|date=2013|deadurl=no|archiveurl=https://web.archive.org/web/20150908025935/http://www.drugs.com/breastfeeding/phenobarbital.html|archivedate=8 September 2015|df=}}
9. ^{{cite book|last1=Stevens|first1=George M. Brenner, Craig W.|title=Pharmacology|date=2013|publisher=Elsevier/Saunders|location=Philadelphia, PA|isbn=978-1-4557-0278-7|page=204|edition=4th|url=https://books.google.com/books?id=Cd39SN6OBiMC&pg=PA204|deadurl=no|archiveurl=https://web.archive.org/web/20170904150548/https://books.google.com/books?id=Cd39SN6OBiMC&pg=PA204|archivedate=2017-09-04|df=}}
10. ^{{cite book|last1=Engel|first1=Jerome|title=Epilepsy : a comprehensive textbook|date=2008|publisher=Wolters Kluwer Health/Lippincott Williams & Wilkins|location=Philadelphia|isbn=978-0-7817-5777-5|page=1431|edition=2nd|url=https://books.google.ca/books?id=3ZktoDp7tZoC&pg=PA1431|deadurl=no|archiveurl=https://web.archive.org/web/20160305041712/https://books.google.ca/books?id=3ZktoDp7tZoC&pg=PA1431|archivedate=2016-03-05|df=}}
11. ^{{cite web|title=WHO Model List of Essential Medicines (19th List)|url=http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|work=World Health Organization|accessdate=8 December 2016|date=April 2015|deadurl=no|archiveurl=https://web.archive.org/web/20161213052708/http://www.who.int/medicines/publications/essentialmedicines/EML_2015_FINAL_amended_NOV2015.pdf?ua=1|archivedate=13 December 2016|df=}}
12. ^1 {{cite journal|last=Newton|first=CR|title=Epilepsy in poor regions of the world.|journal=Lancet|date=29 September 2012|volume=380|issue=9848|pages=1193–201|doi=10.1016/S0140-6736(12)61381-6|pmid=23021288}}
13. ^{{cite web| url = http://www.nice.org.uk/page.aspx?o=CG020NICEguideline| title = CG20 Epilepsy in adults and children: NICE guideline| accessdate = 2006-09-06| author = NICE| authorlink = National Institute for Health and Clinical Excellence| date = 2005-10-27| publisher = NHS| deadurl = yes| archiveurl = https://web.archive.org/web/20061009090708/http://www.nice.org.uk/page.aspx?o=CG020NICEguideline| archivedate = 2006-10-09| df = }}
14. ^1 British National Formulary 51
15. ^{{Cite journal|last=Nolan|first=Sarah J.|last2=Tudur Smith|first2=Catrin|last3=Pulman|first3=Jennifer|last4=Marson|first4=Anthony G.|date=2013-01-31|title=Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic-clonic seizures|journal=The Cochrane Database of Systematic Reviews|issue=1|pages=CD002217|doi=10.1002/14651858.CD002217.pub2|issn=1469-493X|pmid=23440786}}
16. ^{{cite journal|last1=Nolan|first1=SJ|last2=Marson|first2=AG|last3=Weston|first3=J|last4=Tudur Smith|first4=C|title=Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.|journal=The Cochrane Database of Systematic Reviews|date=15 December 2016|volume=12|pages=CD001904|doi=10.1002/14651858.CD001904|pmid=27976799}}
17. ^{{cite book| title =British National Formulary for Children| chapter = 4.8.2 Drugs used in status epilepticus| author = British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health and Neonatal and Paediatric Pharmacists Group| year= 2006| isbn = 978-0-85369-676-6| page = 269| publisher =BMJ Publishing| location =London| title-link = British National Formulary for Children}}
18. ^{{cite journal|vauthors=Kälviäinen R, Eriksson K, Parviainen I | title = Refractory generalised convulsive status epilepticus : a guide to treatment| journal = CNS Drugs| volume = 19| issue = 9| pages = 759–68| year = 2005| pmid = 16142991| doi = 10.2165/00023210-200519090-00003}}
19. ^{{cite book|last=Moshé|first=edited by Simon Shorvon, Emilio Perucca, Jerome Engel Jr.; foreword by Solomon|title=The treatment of epilepsy|year=2009|publisher=Wiley-Blackwell|location=Chichester, UK|isbn=978-1-4443-1667-4|page=587|url=https://books.google.com/books?id=rFFzFzZJtasC&pg=PA587|edition=3rd|deadurl=no|archiveurl=https://web.archive.org/web/20160521102931/https://books.google.com/books?id=rFFzFzZJtasC&pg=PA587|archivedate=2016-05-21|df=}}
20. ^{{cite book| title =British National Formulary for Children| chapter = 4.8.1 Control of epilepsy| pages = 255–6| author = British Medical Association, Royal Pharmaceutical Society of Great Britain, Royal College of Paediatrics and Child Health and Neonatal and Paediatric Pharmacists Group| year= 2006| isbn = 978-0-85369-676-6| publisher =BMJ Publishing| location =London| title-link = British National Formulary for Children}}
21. ^{{cite book|author1=John M. Pellock |author2=W. Edwin Dodson |author3=Blaise F. D. Bourgeois | title = Pediatric Epilepsy| date = 2001-01-01| publisher = Demos Medical Publishing| isbn = 978-1-888799-30-9| page = 152}}
22. ^{{cite web |url = http://www.emedicine.com/NEURO/topic240.htm |title = Neonatal Seizures |accessdate = 2006-09-06 |author = Raj D Sheth |date = 2005-03-30 |work = eMedicine |publisher = WebMD |deadurl = no |archiveurl = https://web.archive.org/web/20060709212952/http://www.emedicine.com/NEURO/topic240.htm |archivedate = 2006-07-09 |df = }}
23. ^{{cite journal| author = Booth D, Evans DJ| title = Anticonvulsants for neonates with seizures| journal = Cochrane Database of Systematic Reviews| issue = 3| year = 2004| doi = 10.1002/14651858.CD004218.pub2| pmid = 15495087| url = http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD004218/pdf_fs.html| accessdate = 2006-09-06| pages = CD004218| editor1-last = Booth| editor1-first = David }}
24. ^{{cite journal |url=http://www.aafp.org/afp/980700ap/miller.html |title=Management of Withdrawal Syndromes and Relapse Prevention in Drug and Alcohol Abuse |journal=American Family Physician |volume=58 |issue=1 |pages=139–46 |accessdate=2011-03-31 |deadurl=no |archiveurl=https://web.archive.org/web/20101228033819/http://www.aafp.org/afp/980700ap/miller.html |archivedate=2010-12-28 |df= |date=July 1998 |last1=Gold |first1=Mark S. |last2=Miller |first2=Norman S. |pmid=9672434 }}
25. ^{{cite book|last1=Aschenbrenner|first1=Diane S.|last2=Venable|first2=Samantha J.|title=Drug Therapy in Nursing|date=2009|publisher=Lippincott Williams & Wilkins|isbn=9780781765879|page=277|url=https://books.google.ca/books?id=5zd_W_PUwvYC&pg=PA277|language=en}}
26. ^{{Cite book|title=Harrison's Principles of Internal Medicine, 19th edition|last=Kasper|first=Dennis|publisher=Mc Graw Hill|isbn=978-0071802154|location=|pages=2002|quote=Bilirubin concentrations during phenobarbital administration do not return to normal but are typically in the range of 51-86 µmol/L (3-5 mg/dL). Although the incidence of kernicterus in CN-II is low, instances have occurred, not only in infants but also in adolescents and adults, often in the setting of an intercurrent illness, fasting, or another factor that temporarily raises the serum bilirubin concentration above baseline and reduces serum albumin levels. For this reason, phenobarbital therapy is highly recommended, a single bedtime dose often sufficing to maintain clinically safe serum bilirubin concentrations.|via=|date=2015-04-08}}
27. ^{{cite web |url=http://www.doh.wa.gov/portals/1/Documents/Pubs/422-109-DeathWithDignityAct2015.pdf |title=Archived copy |accessdate=2017-06-07 |deadurl=no |archiveurl=https://web.archive.org/web/20170215140943/http://www.doh.wa.gov/portals/1/Documents/Pubs/422-109-DeathWithDignityAct2015.pdf |archivedate=2017-02-15 |df= }}
28. ^{{cite journal|last1=López-Muñoz|first1=F|last2=Ucha-Udabe|first2=R|last3=Alamo|first3=C|title=The history of barbiturates a century after their clinical introduction.|journal=Neuropsychiatric Disease and Treatment|date=December 2005|volume=1|issue=4|pages=329–43|pmid=18568113|pmc=2424120|quote=Despite their widespread use during the first half of the 20th century, no barbiturate succeeded in eliminating the main drawbacks of these drugs, which were the phenomena of dependence and death by overdose}}
29. ^[https://books.google.ee/books?id=fQSrJurXnDkC&q=phenobarbital+abuse&dq=phenobarbital+abuse&hl=et&sa=X&ved=0ahUKEwiP7r2IhfbaAhVJ_KQKHVrmDK84FBDoAQgyMAI Barbiturate abuse in the United States, 1973]
30. ^1 {{Cite web|url=https://reference.medscape.com/drug/luminal-phenobarbital-343017|title=Phenobarbital dosing, indications, interactions, adverse effects, and more|website=reference.medscape.com|access-date=2019-03-27}}
31. ^{{cite journal|last1=Brodie|first1=Martin J.|last2=Mintzer|first2=Scott|last3=Pack|first3=Alison M.|last4=Gidal|first4=Barry E.|last5=Vecht|first5=Charles J.|last6=Schmidt|first6=Dieter|title=Enzyme induction with antiepileptic drugs: Cause for concern?|journal=Epilepsia|date=January 2013|volume=54|issue=1|pages=11–27|doi=10.1111/j.1528-1167.2012.03671.x|pmid=23016553}}
32. ^{{cite journal | journal = Epilepsia | year = 1988| volume = 29 Suppl 3| pages = S15–9| title = Children of school age: the influence of antiepileptic drugs on behavior and intellect| author = Trimble MR|author2=Cull C| pmid = 3066616| doi = 10.1111/j.1528-1157.1988.tb05805.x}}
33. ^1 {{cite web| url = http://www.emedicine.com/MED/topic207.htm| title = Barbiturate Toxicity| accessdate = 2006-09-14| author = Rania Habal| date = 2006-01-27| work = eMedicine| publisher = WebMD| deadurl = no| archiveurl = https://web.archive.org/web/20080720013401/http://www.emedicine.com/med/topic207.htm| archivedate = 2008-07-20| df = }}
34. ^{{cite web |url= https://www.nlm.nih.gov/medlineplus/ency/article/000951.htm |title= Barbiturate intoxication and overdose |accessdate= 15 July 2008 |publisher= MedLine Plus |deadurl= no |archiveurl= https://web.archive.org/web/20081001212130/http://www.nlm.nih.gov/medlineplus/ency/article/000951.htm |archivedate= 1 October 2008 |df= }}
35. ^{{cite news | title = Abbie Hoffman Committed Suicide Using Barbiturates, Autopsy Shows | last = King | first = Wayne | date = April 19, 1989 | work = The New York Times | url = https://query.nytimes.com/gst/fullpage.html?sec=health&res=950DE7D61F38F93AA25757C0A96F948260 | accessdate = 2008-04-09 | deadurl = no | archiveurl = https://web.archive.org/web/20071016124522/http://query.nytimes.com/gst/fullpage.html?sec=health&res=950DE7D61F38F93AA25757C0A96F948260 | archivedate = October 16, 2007 | df = }}
36. ^{{cite web |url=http://www.history.com/this-day-in-history/heavens-gate-cult-members-found-dead |title=Heaven's Gate cult members found dead |work=History Channel |date= |accessdate=September 17, 2014 |deadurl=no |archiveurl=https://web.archive.org/web/20141026204231/http://www.history.com/this-day-in-history/heavens-gate-cult-members-found-dead |archivedate=October 26, 2014 |df= }}
37. ^{{Citation|last=Lewis|first=Cassaundra B.|title=Phenobarbital|date=2019|url=http://www.ncbi.nlm.nih.gov/books/NBK532277/|work=StatPearls|publisher=StatPearls Publishing|pmid=30335310|access-date=2019-03-27|last2=Adams|first2=Ninos}}
38. ^{{Citation|last=Brust|first=John C.M.|title=Alcohol and the nervous system – Chapter 8 – Acute withdrawal: diagnosis and treatment|date=2014|url=https://linkinghub.elsevier.com/retrieve/pii/B9780444626196000082|work=Handbook of Clinical Neurology|volume=125|pages=123–131|series=|publication-place=|publisher=Elsevier|language=en|doi=10.1016/b978-0-444-62619-6.00008-2|isbn=9780444626196|access-date=2019-03-28}}
39. ^{{Citation|last=Flynn|first=Sean|title=Pharmacology and Therapeutics for Dentistry|date=2017|url=https://linkinghub.elsevier.com/retrieve/pii/B9780323393072000126|work=|volume=|pages=176–192|chapter=Chapter 12: Anticonvulsants|publisher=Elsevier|language=en|doi=10.1016/b978-0-323-39307-2.00012-6|isbn=9780323393072|access-date=2019-03-28|last2=Babi|first2=M. Ali}}
40. ^{{cite book| author = Thomas, WB| chapter = Seizures and narcolepsy| editor = Dewey, Curtis W.| title = A Practical Guide to Canine and Feline Neurology| publisher = Iowa State Press| location = Ames, Iowa| year = 2003| isbn = 978-0-8138-1249-6}}
41. ^{{cite web |last = Dodman |first = Nicholas |title = Feline Hyperesthesia (FHS) |publisher = PetPlace.com |url = http://www.petplace.com/cats/feline-hyperesthesia/page1.aspx |accessdate = 2011-11-17 |deadurl = no |archiveurl = https://web.archive.org/web/20111123162526/http://www.petplace.com/cats/feline-hyperesthesia/page1.aspx |archivedate = 2011-11-23 |df = }}
42. ^{{cite book| editor= Kahn, Cynthia M., Line, Scott, Aiello, Susan E. (ed.)| title= The Merck Veterinary Manual| date= February 8, 2005| publisher= John Wiley & Sons| edition= 9th| isbn= 978-0-911910-50-6| author= Editor, Cynthia M. Kahn; associate editor Scott Line| title-link= Merck Veterinary Manual}}
43. ^{{cite book| last = Sneader| first = Walter| title = Drug Discovery| date= 2005-06-23| publisher = John Wiley and Sons| isbn = 978-0-471-89979-2| page = 369}}
44. ^{{cite web |url = http://www.whonamedit.com/doctor.cfm/2764.html |title = Alfred Hauptmann |accessdate = 2006-09-06 |author = Ole Daniel Enersen |deadurl = no |archiveurl = https://web.archive.org/web/20061109210437/http://www.whonamedit.com/doctor.cfm/2764.html |archivedate = 2006-11-09 |df = }}
45. ^{{cite book| last = Scott| first = Donald F| title = The History of Epileptic Therapy| date = 1993-02-15| publisher = Taylor & Francis| isbn = 978-1-85070-391-4| pages = 59–65}}
46. ^{{cite news|last=Zoech|first=Irene|title=Named: the baby boy who was Nazis' first euthanasia victim|url=https://www.telegraph.co.uk/news/worldnews/europe/germany/1443967/Named-the-baby-boy-who-was-Nazis-first-euthanasia-victim.html|accessdate=1 November 2013|newspaper=The Telegraph|date=12 October 2003|quote=The case was to provide the rationale for a secret Nazi decree that led to 'mercy killings' of almost 300,000 mentally and physically handicapped people. The Kretschmars wanted their son dead but most of the other children were forcibly taken from their parents to be killed.|deadurl=no|archiveurl=https://web.archive.org/web/20131216194326/http://www.telegraph.co.uk/news/worldnews/europe/germany/1443967/Named-the-baby-boy-who-was-Nazis-first-euthanasia-victim.html|archivedate=16 December 2013|df=}}
47. ^{{cite news|title=Killing Babies, Compassionately|url=http://www.weeklystandard.com/Content/Public/Articles/000/000/012/003dncoj.asp|accessdate=1 November 2013|newspaper=Weekly Standard|date=26 March 2006|author=Wesley J. Smith|quote=Hitler later signed a secret decree permitting the euthanasia of disabled infants. Sympathetic physicians and nurses from around the country--many not even Nazi party members--cooperated in the horror that followed. Formal 'protective guidelines' were created, including the creation of a panel of 'expert referees,' which judged which infants were eligible for the program.}}
48. ^{{cite web|last=Kaelber|first=Lutz|title=Kinderfachabteilung Ansbach|url=http://www.uvm.edu/~lkaelber/children/ansbach/ansbach.html|work=Sites of Nazi "Children's 'Euthanasia'" Crimes and Their Commemoration in Europe|publisher=University of Vermont|accessdate=1 November 2013|date=8 March 2013|quote=In the late 1980s, important developments occurred at the clinic that led to the first publication on the subject and the display of two plaques. Dr Reiner Weisenseel wrote his dissertation under Dr Athen, then the director of the Ansbacher Bezirkskrankenhaus, on the involvement of the clinic in Euthanasia crimes, including the operation of the Kinderfachabteilung. In 1988 two members of the Green Party as well as the regional diet (Bezirkstag) were horrified to find portraits of physicians involved in Nazi euthanasia crimes among the honorary display of medical personnel in the administrative building, and they successfully petitioned to have these portraits removed. Since 1992 a plaque hangs in the entry hall way of the administrative building. It reads: 'In the Third Reich the Ansbach facility delivered to their death more than 2000 of the patients entrusted to it as life unworthy of living: They were transferred to killing facilities or starved to death. In their own way many people incurred responsibility.' It continues: 'Half a century later full of shame we commemorate the victims and call to remember the Fifth Commandment.' The killing of children specifically transferred to the clinic to be murdered is not noted. The plaque does not address that that euthanasia victims were not only starved or transported to gassing facilities but killed using barbiturates on site.|deadurl=no|archiveurl=https://web.archive.org/web/20131103075613/http://www.uvm.edu/~lkaelber/children/ansbach/ansbach.html|archivedate=3 November 2013|df=}}
49. ^{{cite web | last = Binder | first = Johann | title = Die Heil- und Pflegeanstalt Ansbach während des Nationalsozialismus | url = http://www.bezirksklinikum-ansbach.de/fileadmin/user_upload/bilder/Ansbach/BklMfr_Flyer_61_AN_Gedenkorte_DRUCK_neu.pdf | work = Bezirksklinikum Ansbach | publisher = Bezirkskliniken Mittelfranken | accessdate = 1 November 2013 | language = German | date = October 2011 | deadurl = yes | archiveurl = https://web.archive.org/web/20131103130325/http://www.bezirksklinikum-ansbach.de/fileadmin/user_upload/bilder/Ansbach/BklMfr_Flyer_61_AN_Gedenkorte_DRUCK_neu.pdf | archivedate = 3 November 2013 | df = }}
50. ^{{cite web|last=Kaelber|first=Lutz|title=Jewish Children with Disabilities and Nazi "Euthanasia" Crimes|url=http://www.uvm.edu/~lkaelber/children/leipzigdoesen/bull2013-Kaelber1.pdf|work=The Bulletin of the Carolyn and Leonard Miller Center for Holocaust Studies|publisher=University of Vermont|accessdate=1 November 2013|date=Spring 2013|quote=Two Polish physicians reported at the time that 235 children from ages up to 14 were listed in the booklet, of whom 221 had died. An investigation revealed that the medical records of the children had been falsified, as those records showed a far lower dosage of Luminal given to them than was entered into the Luminal booklet. For example, the medical records for Marianna N. showed for 16 January 1943 (she died on that day) a dosage of 0.1 g of Luminal, whereas the Luminal booklet showed the actual dosage as 0.4 g, or four times the dosage recommended for her body weight.|deadurl=no|archiveurl=https://web.archive.org/web/20131103080046/http://www.uvm.edu/~lkaelber/children/leipzigdoesen/bull2013-Kaelber1.pdf|archivedate=3 November 2013|df=}}
51. ^{{cite journal|doi=10.1016/j.brainresbull.2008.09.002|pmid=18848972|title=The role of psychopharmacology in the medical abuses of the Third Reich: From euthanasia programmes to human experimentation|journal=Brain Research Bulletin|volume=77|issue=6|pages=388–403|year=2008|last1=López-Muñoz|first1=Francisco|last2=Alamo|first2=Cecilio|last3=García-García|first3=Pilar|last4=Molina|first4=Juan D.|last5=Rubio|first5=Gabriel}}
52. ^{{cite journal| author = Rachel Sheremeta Pepling| date=June 2005| title = Phenobarbital| journal = Chemical and Engineering News| volume = 83| issue = 25| url = http://pubs.acs.org/cen/coverstory/83/8325/8325phenobarbital.html| accessdate = 2006-09-06 }}
53. ^{{cite book|author1=John M. Pellock |author2=W. Edwin Dodson |author3=Blaise F. D. Bourgeois | title = Pediatric Epilepsy| date = 2001-01-01| publisher = Demos Medical Publishing| isbn = 978-1-888799-30-9| page = 169}}
54. ^{{cite web |url= http://www.emedicine.com/neuro/topic134.htm |title= Febrile Seizures |accessdate = 2006-09-06 |author= Robert Baumann |date= 2005-02-14 |work = eMedicine |publisher= WebMD |archiveurl = https://web.archive.org/web/20060906023934/http://www.emedicine.com/NEURO/topic134.htm |archivedate = 2006-09-06 }}
55. ^{{cite web |url = http://www.sign.ac.uk/pdf/sign81.pdf |title = Diagnosis and management of epilepsies in children and young people |accessdate = 2006-09-07 |author = various |date = March 2005 |publisher = Scottish Intercollegiate Guidelines Network |pages = 15 |archiveurl = https://web.archive.org/web/20060610140906/http://www.sign.ac.uk/pdf/sign81.pdf |archivedate = 2006-06-10 }}
56. ^1 {{cite book|author1=Furniss, Brian|author2=Hannaford, Antony|author3=Smith, Peter|author4=Tatchell, Austin|title=Vogel's Textbook of Practical Organic Chemistry 5th Ed.|year=1996|publisher=Longman Science & Technical|location=London|isbn=978-0-582-46236-6|pages=1174–1179|url=https://archive.org/details/TextbookOfPracticalOrganicChemistry5thEd|deadurl=no|archiveurl=https://web.archive.org/web/20160311011821/https://archive.org/details/TextbookOfPracticalOrganicChemistry5thEd|archivedate=2016-03-11|df=}}
57. ^{{cite book|last1=Adams|first1=Roger|title=Organic Reactions, Volume 9|date=1957|publisher=John Wiley & Sons, Inc.|location=New York|isbn=978-0-471-00726-5|url=http://www.wiley.com/WileyCDA/WileyTitle/productCd-0471007269.html|accessdate=18 July 2014|deadurl=no|archiveurl=https://web.archive.org/web/20141031013218/http://www.wiley.com/WileyCDA/WileyTitle/productCd-0471007269.html|archivedate=31 October 2014|df=}}
58. ^{{cite journal|last1=Adams|first1=Roger|last2=Thal|first2=A. F.|title=Ethyl Phenylacetate|journal=Organic Syntheses|date=1922|volume=2|page=27|doi=10.15227/orgsyn.002.0027}}
59. ^{{cite journal|last1=Meyer|first1=G. M.|last2=Levene|first2=P. A.|title=Diethyl phenylmalonate|journal=Organic Syntheses|date=1936|volume=16|page=33|doi=10.15227/orgsyn.016.0033}}
60. ^{{cite journal|last1=Chamberlain|first1=J. S.|last2=Chap|first2=J.J.|last3=Doyle|first3=J. E.|last4=Spaulding|first4=L. B.|title=The Synthesis of 5,5-Alkylphenylbarbituric Acids|journal=Journal of the American Chemical Society|date=1935|volume=57|issue=2|pages=352–354|doi=10.1021/ja01305a036}}
61. ^{{cite journal|last1=Nelson|first1=William L.|last2=Cretcher|first2=Leonard H.|title=The Preparation of Ethyl Phenylmalonate and of 5-Phenyl-beta-hydroxyethylbarbituric acid|journal=Journal of the American Chemical Society|date=1928|volume=50|issue=10|pages=2758–2762|doi=10.1021/ja01397a029}}
62. ^{{cite journal|last1=Makosza|first1=M.|last2=Jonczyk|first2=A|title=Phase-Transfer Alkylation of Nitriles: 2-Phenylbutyronitrile|journal=Organic Syntheses|date=1976|volume=55|page=91|doi=10.15227/orgsyn.055.0091}}
63. ^{{cite web|last1=Marc|first1=Inman Nyack|last2=Haverstraw|first2=N.|last3=Bilter|first3=William|title=Preparation of Phenobarbital (US2358072, 1944)|url=https://docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US2358072.pdf|website=Google Patents|publisher=Kay-Fries Chemicals, Inc.|accessdate=30 October 2014|deadurl=no|archiveurl=https://web.archive.org/web/20160412063222/https://docs.google.com/viewer?url=patentimages.storage.googleapis.com%2Fpdfs%2FUS2358072.pdf|archivedate=12 April 2016|df=}}
64. ^{{cite web |url=http://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf |title=DEA Diversion Control Division |accessdate=2016-04-13 |deadurl=no |archiveurl=https://web.archive.org/web/20160417085659/http://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf |archivedate=2016-04-17 |df= }} pp 12 printed PDF 23.I.2016
65. ^{{cite web |url=http://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf |title=DEA Diversion Control Division |accessdate=2016-04-13 |deadurl=no |archiveurl=https://web.archive.org/web/20160417085659/http://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf |archivedate=2016-04-17 |df= }} page 1,7, 12, accessed 23.I.2016

External links

  • U.S. National Library of Medicine: Drug Information Portal – Phenobarbital
{{Anticonvulsants}}{{Hypnotics and sedatives}}{{Navboxes
| title = Pharmacodynamics
| titlestyle = background:#ccccff
| list1 ={{GABAA receptor positive modulators}}{{Ionotropic glutamate receptor modulators}}{{Xenobiotic-sensing receptor modulators}}
}}{{Authority control}}{{portal bar|Pharmacy and pharmacology|Medicine}}

8 : Barbiturates|Anxiolytics|Hypnotics|World Health Organization essential medicines|IARC Group 2B carcinogens|GABAA receptor positive allosteric modulators|Bayer AG|RTT
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/11 23:41:13